Skip to main content
Terug
MEDGF logo

Medacta Group S.A.

Datakwaliteit: 100%
Overbought
MEDGF
OTC Healthcare Medical - Devices
€ 83,91
€ 0,00 (0,00%)
Marktkapitalisatie: 1,67B
Dagbereik
€ 83,91 € 83,91
52-Weeksbereik
€ 83,91 € 83,91
Volume
112
50D / 200D Gem.
€ 83,91 / € 83,91
Vorige Slotkoers
€ 83,91

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E 17,4 0,4
P/B 3,7 2,9
ROE % 23,0 3,7
Net Margin % 14,0 3,8
Rev Growth 5Y % 17,3 10,0
D/E 0,6 0,2

Belangrijkste Punten

Revenue grew 17,33% annually over 5 years — strong growth
Earnings grew 31,84% over the past year
ROE of 23,00% indicates high profitability
Generating 29,89M in free cash flow
PEG of 0,47 suggests growth is underpriced

Groei

Revenue Growth (5Y)
17,33%
Revenue (1Y)16,51%
Earnings (1Y)31,84%
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
23,00%
ROIC12,07%
Net Margin13,97%
Op. Margin16,80%

Veiligheid

Debt / Equity
0,58
Current Ratio2,08
Interest Coverage16,87

Waardering

P/E Ratio
17,39
P/B Ratio3,66
EV/EBITDA16,44
Dividend Yield0,01%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 16,51% Revenue Growth (3Y) 16,06%
Earnings Growth (1Y) 31,84% Earnings Growth (3Y) 42,44%
Revenue Growth (5Y) 17,33% Earnings Growth (5Y) 16,86%
Profitability
Revenue (TTM) 688,06M Net Income (TTM) 96,09M
ROE 23,00% ROA 10,48%
Gross Margin 64,13% Operating Margin 16,80%
Net Margin 13,97% Free Cash Flow (TTM) 29,89M
ROIC 12,07% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,58 Current Ratio 2,08
Interest Coverage 16,87 Dividend Yield 0,01%
Valuation
P/E Ratio 17,39 P/B Ratio 3,66
P/S Ratio 2,43 PEG Ratio 0,47
EV/EBITDA 16,44 Dividend Yield 0,01%
Market Cap 1,67B Enterprise Value 1,90B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 688,06M 590,58M 510,78M 437,12M 363,13M
Net Income 96,09M 72,89M 47,36M 46,25M 51,52M
EPS (Diluted) 4,81 3,65 2,37 2,31 2,58
Gross Profit 441,27M 399,44M 347,85M 305,26M 261,25M
Operating Income 115,62M 90,83M 74,44M 61,46M 58,78M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 916,65M 792,18M 695,87M 584,49M 489,27M
Total Liabilities 460,57M 412,51M 365,83M 309,83M 262,87M
Shareholders' Equity 456,08M 379,66M 330,04M 274,66M 226,40M
Total Debt 262,48M 241,21M 201,98M 170,25M 132,66M
Cash & Equivalents 33,18M 31,59M 20,79M 32,26M 20,40M
Current Assets 449,54M 395,38M 348,47M 283,66M 228,03M
Current Liabilities 216,47M 157,55M 149,42M 89,06M 136,56M

Strategiescores

This stock passed the criteria for 4 strategies

Score = fit strength (0–100)
Rank = position among all matches
Growth + Value Growth at a Reasonable Price (Peter Lynch)
#78 of 326
64
Growth Growth Investing (Philip Fisher)
#142 of 154
21
Custom Balanced Risk
#83 of 148
45
Custom Lower Risk
#58 of 136
47

Recente Activiteit

Ingestapt Growth Investing (Philip Fisher)
Mar 24, 2026
Ingestapt Growth at a Reasonable Price (Peter Lynch)
Mar 24, 2026
Ingestapt Balanced Risk
Mar 24, 2026
Ingestapt Lower Risk
Mar 24, 2026